Burning Rock Biotech (BNR) Competitors

$17.18 -1.38 (-7.41%)

As of 11:51 AM Eastern

BNR vs. PSNL, CSTL, MCTA, FLGT, and TOI

Should you buy Burning Rock Biotech stock or one of its competitors? MarketBeat compares Burning Rock Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Burning Rock Biotech include Personalis (PSNL), Castle Biosciences (CSTL), Charming Medical (MCTA), Fulgent Genetics (FLGT), and Oncology Institute (TOI). These companies are all part of the "healthcare" industry.

How does Burning Rock Biotech compare to Personalis?

Personalis (NASDAQ:PSNL) and Burning Rock Biotech (NASDAQ:BNR) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

In the previous week, Personalis had 10 more articles in the media than Burning Rock Biotech. MarketBeat recorded 11 mentions for Personalis and 1 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 1.89 beat Personalis' score of 0.20 indicating that Burning Rock Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Personalis	Neutral
Burning Rock Biotech	Very Positive

Personalis presently has a consensus price target of $11.00, suggesting a potential upside of 69.49%. Given Personalis' stronger consensus rating and higher possible upside, equities analysts clearly believe Personalis is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Personalis	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Burning Rock Biotech has higher revenue and earnings than Personalis. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Personalis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Personalis	$69.65M	9.76	-$81.27M	-$1.02	N/A
Burning Rock Biotech	$77.16M	2.34	-$7.92M	-$0.79	N/A

61.9% of Personalis shares are held by institutional investors. Comparatively, 30.0% of Burning Rock Biotech shares are held by institutional investors. 4.2% of Personalis shares are held by insiders. Comparatively, 30.3% of Burning Rock Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Personalis has a beta of 1.96, meaning that its stock price is 96% more volatile than the broader market. Comparatively, Burning Rock Biotech has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market.

Burning Rock Biotech has a net margin of -10.27% compared to Personalis' net margin of -148.11%. Burning Rock Biotech's return on equity of -9.98% beat Personalis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Personalis	-148.11%	-43.52%	-32.92%
Burning Rock Biotech	-10.27%	-9.98%	-6.69%

Summary

Personalis and Burning Rock Biotech tied by winning 8 of the 16 factors compared between the two stocks.

How does Burning Rock Biotech compare to Castle Biosciences?

Castle Biosciences (NASDAQ:CSTL) and Burning Rock Biotech (NASDAQ:BNR) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

Castle Biosciences currently has a consensus target price of $44.57, indicating a potential upside of 133.18%. Given Castle Biosciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Castle Biosciences is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Castle Biosciences	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Castle Biosciences had 11 more articles in the media than Burning Rock Biotech. MarketBeat recorded 12 mentions for Castle Biosciences and 1 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 1.89 beat Castle Biosciences' score of -0.08 indicating that Burning Rock Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Castle Biosciences	Neutral
Burning Rock Biotech	Very Positive

Castle Biosciences has a net margin of -3.78% compared to Burning Rock Biotech's net margin of -10.27%. Castle Biosciences' return on equity of -2.77% beat Burning Rock Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Castle Biosciences	-3.78%	-2.77%	-2.30%
Burning Rock Biotech	-10.27%	-9.98%	-6.69%

92.6% of Castle Biosciences shares are owned by institutional investors. Comparatively, 30.0% of Burning Rock Biotech shares are owned by institutional investors. 6.1% of Castle Biosciences shares are owned by insiders. Comparatively, 30.3% of Burning Rock Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Burning Rock Biotech has lower revenue, but higher earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than Burning Rock Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Castle Biosciences	$344.23M	1.68	-$24.16M	-$0.44	N/A
Burning Rock Biotech	$77.16M	2.34	-$7.92M	-$0.79	N/A

Castle Biosciences has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market. Comparatively, Burning Rock Biotech has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market.

Summary

Castle Biosciences beats Burning Rock Biotech on 11 of the 17 factors compared between the two stocks.

How does Burning Rock Biotech compare to Charming Medical?

Charming Medical (NASDAQ:MCTA) and Burning Rock Biotech (NASDAQ:BNR) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

In the previous week, Charming Medical had 5 more articles in the media than Burning Rock Biotech. MarketBeat recorded 6 mentions for Charming Medical and 1 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 1.89 beat Charming Medical's score of 1.32 indicating that Burning Rock Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Charming Medical	Positive
Burning Rock Biotech	Very Positive

30.0% of Burning Rock Biotech shares are owned by institutional investors. 30.3% of Burning Rock Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Charming Medical has higher earnings, but lower revenue than Burning Rock Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Charming Medical	N/A	N/A	N/A	N/A	N/A
Burning Rock Biotech	$77.16M	2.34	-$7.92M	-$0.79	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Charming Medical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Charming Medical has a net margin of 0.00% compared to Burning Rock Biotech's net margin of -10.27%. Charming Medical's return on equity of 0.00% beat Burning Rock Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Charming Medical	N/A	N/A	N/A
Burning Rock Biotech	-10.27%	-9.98%	-6.69%

Summary

Charming Medical and Burning Rock Biotech tied by winning 4 of the 8 factors compared between the two stocks.

How does Burning Rock Biotech compare to Fulgent Genetics?

Burning Rock Biotech (NASDAQ:BNR) and Fulgent Genetics (NASDAQ:FLGT) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

In the previous week, Fulgent Genetics had 4 more articles in the media than Burning Rock Biotech. MarketBeat recorded 5 mentions for Fulgent Genetics and 1 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 1.89 beat Fulgent Genetics' score of 0.58 indicating that Burning Rock Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Burning Rock Biotech	Very Positive
Fulgent Genetics	Positive

30.0% of Burning Rock Biotech shares are held by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are held by institutional investors. 30.3% of Burning Rock Biotech shares are held by company insiders. Comparatively, 36.2% of Fulgent Genetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Burning Rock Biotech has higher earnings, but lower revenue than Fulgent Genetics. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Fulgent Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Burning Rock Biotech	$77.16M	2.34	-$7.92M	-$0.79	N/A
Fulgent Genetics	$322.67M	1.46	-$60.51M	-$2.39	N/A

Fulgent Genetics has a consensus target price of $27.00, suggesting a potential upside of 70.66%. Given Fulgent Genetics' stronger consensus rating and higher probable upside, analysts clearly believe Fulgent Genetics is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Burning Rock Biotech has a net margin of -10.27% compared to Fulgent Genetics' net margin of -23.04%. Fulgent Genetics' return on equity of -3.24% beat Burning Rock Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Burning Rock Biotech	-10.27%	-9.98%	-6.69%
Fulgent Genetics	-23.04%	-3.24%	-2.97%

Burning Rock Biotech has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market. Comparatively, Fulgent Genetics has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market.

Summary

Fulgent Genetics beats Burning Rock Biotech on 10 of the 16 factors compared between the two stocks.

How does Burning Rock Biotech compare to Oncology Institute?

Oncology Institute (NASDAQ:TOI) and Burning Rock Biotech (NASDAQ:BNR) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations.

Oncology Institute currently has a consensus target price of $7.00, suggesting a potential upside of 76.54%. Given Oncology Institute's stronger consensus rating and higher possible upside, research analysts clearly believe Oncology Institute is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncology Institute	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Oncology Institute has a net margin of -7.42% compared to Burning Rock Biotech's net margin of -10.27%. Oncology Institute's return on equity of 0.00% beat Burning Rock Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncology Institute	-7.42%	N/A	-24.68%
Burning Rock Biotech	-10.27%	-9.98%	-6.69%

36.9% of Oncology Institute shares are owned by institutional investors. Comparatively, 30.0% of Burning Rock Biotech shares are owned by institutional investors. 8.5% of Oncology Institute shares are owned by insiders. Comparatively, 30.3% of Burning Rock Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Burning Rock Biotech has lower revenue, but higher earnings than Oncology Institute. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Oncology Institute, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncology Institute	$502.73M	0.78	-$60.61M	-$0.37	N/A
Burning Rock Biotech	$77.16M	2.34	-$7.92M	-$0.79	N/A

In the previous week, Oncology Institute had 5 more articles in the media than Burning Rock Biotech. MarketBeat recorded 6 mentions for Oncology Institute and 1 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 1.89 beat Oncology Institute's score of 0.79 indicating that Burning Rock Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Oncology Institute	Positive
Burning Rock Biotech	Very Positive

Oncology Institute has a beta of 0.33, meaning that its stock price is 67% less volatile than the broader market. Comparatively, Burning Rock Biotech has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market.

Summary

Oncology Institute beats Burning Rock Biotech on 10 of the 16 factors compared between the two stocks.

Get Burning Rock Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BNR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BNR vs. The Competition

Export

Metric	Burning Rock Biotech	Technology Services Industry	Business Sector	NASDAQ Exchange
Market Cap	$180.44M	$3.88B	$6.40B	$12.28B
Dividend Yield	N/A	2.10%	3.18%	5.35%
P/E Ratio	-21.71	51.37	30.60	25.35
Price / Sales	2.34	52.18	437.16	73.28
Price / Cash	N/A	39.69	23.10	56.33
Price / Book	2.36	5.37	6.74	6.86
Net Income	-$7.92M	$32.12M	$200.71M	$333.62M
7 Day Performance	2.53%	8.80%	2.12%	0.13%
1 Month Performance	-16.42%	-1.95%	-1.92%	1.96%
1 Year Performance	511.53%	31.72%	36.03%	32.94%

Burning Rock Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BNR Burning Rock Biotech	1.4079 of 5 stars	$17.18 -7.4%	N/A	+611.1%	$180.44M	$77.16M	N/A	1,390	Positive News Gap Down
PSNL Personalis	2.3527 of 5 stars	$6.04 +4.5%	$11.00 +82.1%	+39.2%	$605.29M	$69.65M	N/A	400	Analyst Forecast Gap Down
CSTL Castle Biosciences	3.3601 of 5 stars	$18.63 -2.2%	$46.00 +146.9%	+15.7%	$577.48M	$344.23M	N/A	540	Analyst Forecast
MCTA Charming Medical	N/A	$29.36 +6.8%	N/A	N/A	$497.22M	$5.42M	N/A	49	Positive News Gap Down High Trading Volume
FLGT Fulgent Genetics	3.0188 of 5 stars	$15.80 -0.1%	$27.00 +70.9%	-17.7%	$470.60M	$322.67M	N/A	1,315

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BNR) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Burning Rock Biotech (BNR) Competitors

BNR vs. PSNL, CSTL, MCTA, FLGT, and TOI

How does Burning Rock Biotech compare to Personalis?

Summary

How does Burning Rock Biotech compare to Castle Biosciences?

Summary

How does Burning Rock Biotech compare to Charming Medical?

Summary

How does Burning Rock Biotech compare to Fulgent Genetics?

Summary

How does Burning Rock Biotech compare to Oncology Institute?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNR vs. The Competition

Burning Rock Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Burning Rock Biotech (BNR) Competitors

BNR vs. PSNL, CSTL, MCTA, FLGT, and TOI

How does Burning Rock Biotech compare to Personalis?

Does the media favor PSNL or BNR?

Do analysts prefer PSNL or BNR?

Which has stronger earnings & valuation, PSNL or BNR?

Do insiders and institutionals have more ownership in PSNL or BNR?

Which has more volatility & risk, PSNL or BNR?

Is PSNL or BNR more profitable?

Summary

How does Burning Rock Biotech compare to Castle Biosciences?

Do analysts rate CSTL or BNR?

Does the media favor CSTL or BNR?

Is CSTL or BNR more profitable?

Do insiders and institutionals have more ownership in CSTL or BNR?

Which has higher valuation and earnings, CSTL or BNR?

Which has more risk & volatility, CSTL or BNR?

Summary

How does Burning Rock Biotech compare to Charming Medical?

Does the media favor MCTA or BNR?

Do insiders and institutionals have more ownership in MCTA or BNR?

Which has higher valuation and earnings, MCTA or BNR?

Do analysts rate MCTA or BNR?

Is MCTA or BNR more profitable?

Summary

How does Burning Rock Biotech compare to Fulgent Genetics?

Does the media prefer BNR or FLGT?

Do insiders & institutionals hold more shares of BNR or FLGT?

Which has preferable earnings and valuation, BNR or FLGT?

Do analysts prefer BNR or FLGT?

Is BNR or FLGT more profitable?

Which has more risk & volatility, BNR or FLGT?

Summary

How does Burning Rock Biotech compare to Oncology Institute?

Do analysts recommend TOI or BNR?

Is TOI or BNR more profitable?

Do institutionals & insiders hold more shares of TOI or BNR?

Which has higher valuation and earnings, TOI or BNR?

Does the media favor TOI or BNR?

Which has more risk & volatility, TOI or BNR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNR vs. The Competition

Burning Rock Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools